drugset
drugset / Trial / NCT06582602

A Study of MK-2060 in Healthy Participants (MK-2060-016)

NCT06582602 ↗

Phase 1 Completed 23 enrolled Merck Sharp & Dohme LLC
RandomizedSequentialTriple-blindTreatment

Summary

The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.

Timeline

Start
2024-10-15
Primary completion
2025-04-18
Completion
2025-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-2060 Monoclonal antibody — Intravenous

Indications

venous thromboembolism